Vimian Group (VIMIAN) Fair Value & Analysis
Healthcare · SE · Market cap 17.8B SEK
Fair value as of: Jul 19, 2026
From 24 valuation models · updated yesterday
Fair value updated Jul 19, 2026, revised from kr 1.46 to kr 14.41 (+887.0%) since Jun 24, 2026. Share price +10.3% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 24.92 – kr 43.36 · fair‑value band kr 10.81 – kr 18.02 · the kr 33.75 price screens above the kr 14.41 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Vimian Group (VIMIAN) currently trades at kr 33.75, while our model-based Fair Value estimate is kr 14.41, implying the stock looks roughly 57.3% overvalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Vimian Group generated revenue of 434M SEK at a net margin of 8.5%. Revenue grew 7.9% year over year. It earns a return on equity of 5.3%. Net debt stands at 184M SEK. Fundamentals as of Jul 19, 2026
Our scenario range runs from kr 10.81 (bear case) to kr 18.02 (bull case); at kr 33.75, the current price sits above that range. The share trades about 26% below its 52-week high and 40% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at -57%, VIMIAN screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Vimian Group reported revenue of kr 425M in FY2025 versus kr 173M in FY2021, a compound +25.1%/yr. Reported net income was kr 31.3M in FY2025, compounding +47.6%/yr from FY2021.
Is VIMIAN fairly valued? → Check now
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $472.80 | $190.31 | -60% |
| Danaher Corporation DAP | €154.75 | €112.34 | -27% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| Lonza Group LONN | CHF 499.00 | CHF 134.15 | -73% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Agilent Technologies, Inc A | $126.49 | $63.09 | -50% |
| Waters Corporation WAT | $363.18 | $113.71 | -69% |
| IQVIA Holdings IQV | $182.17 | $119.25 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0100 | +102% |
| Illumina, Inc ILMN | $191.20 | $95.51 | -50% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vimian Group (VIMIAN) undervalued?
What is the fair value of VIMIAN?
What is the quality score of VIMIAN?
What is the revenue of Vimian Group (VIMIAN)?
What is the net profit margin of VIMIAN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Vimian Group analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.